University of Queensland research will determine which patients are least likely to survive melanoma, in an effort to help them beat the disease, thanks to a $200,000 Cancer Council grant.
The research will focus on thin melanomas, which account for the overwhelming majority of melanoma diagnoses in Queensland.
University of Queensland Diamantina Institute Associate Professor Kiarash Khosrotehrani said although survival rates for patients with thin melanoma were high overall, up to four per cent of patients don’t survive 20 years.
“Usually when melanomas are thinner than one millimetre when detected, rates of survival are good – about 96 per cent of patients are still alive 20 years later,” Prof Khosrotehrani said.
“But the remaining four per cent who don’t survive 20 years is a really large group, as thin melanomas represent the overwhelming majority.
“If we can find predictors which identify those most at risk of not surviving thin melanomas, we can target them with more interventions.
“Predictors might relate to gender, the number of melanomas a person has, or the strength of the immune response they can mount.
“The study will also be looking for biomarkers – molecules in the blood or genetic variants that might indicate a patient is at greater risk.”
The project will bring together researchers from the Australian Skin and Skin Cancer Research Centre (ASSC) and the Queensland Melanoma Collaborative, which also comprises QIMR-Berghofer and Cancer Council.
The study will use data collected over 30 years to compare the traits of thin melanoma victims to those of the survivors.
Cancer Council Queensland spokesperson Katie Clift said more than 3600 Queenslanders were diagnosed with melanoma each year.
“Queensland still has the highest rates of skin cancer in the world – far higher than any other jurisdiction nationally or internationally,” Ms Clift said.
“We’re proud to be funding this local research, to improve survival rates for Queenslanders diagnosed with melanoma.”
Between 2004 and 2013, 68 per cent of the 29,588 invasive melanomas diagnosed in Queensland were categorised as thin (less than or equal to 1mm in thickness). 26 per cent were thick, and six per cent had unknown thickness information.
The University of Queensland research grant of $200,000 over two years is one of 10 research projects Cancer Council Queensland has funded in 2017/18.
A full list of Cancer Council’s 2017/18 research grants is available online at cancerqld.org.au.
More information about Cancer Council Queensland is available on 13 11 20 or cancerqld.org.au.
For more information or interviews, please contact:
Media and Spokesperson,
Cancer Council Queensland
Phone: (07) 3634 5372
Mobile: 0409 001 171
CCQ Project Grants 2017/18
|Dr Li Zhang||Griffith University
|Prevention of central venous catheter infection and occlusion by needleless connector design and disinfection in haematology-oncology patients|
|Dr Antiopi Varelias||QIMR Berghofer Medical Research Institute
|Understanding the interplay between cytokines and intestinal dysbiosis following stem cell transplantation|
|Prof Alpha Yap||The University of Queensland
|Down-regulation of RhoA signaling mediates HGF/MET-induced tumour progression
|Dr James Wells||The University of Queensland
|Memory CD8+ T-cell function in squamous cell carcinoma|
|Dr Siok-Keen Tey||QIMR Berghofer Medical Research Institute
|Treatment of chronic graft-versus-host disease with regulatory T cell-directed therapy — insights from gene-marking|
|A/Prof Kiarash Khosrotehrani||UQ Diamantina Institute
|Predictors of mortality in thin melanomas|
|Dr Lionel Hebbard
|James Cook University||Clarifying the controversial role of fructose in liver cancer|
|Prof Elizabeth Isenring
|Bond University||Supplemental Prophylactic Intervention for Chemotherapy-induced Nausea and Emesis (SPICE) trial|
|Dr Graham Leggatt||The University of Queensland
|Local targeting of immunomodulatory molecules on CD8 T cells in non-melanoma skin cancer|
|Dr Jyotsna Batra||Queensland University of Technology
|Genetic association study of miRSNPs with risk and prognosis of prostate cancer|